Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006654 · ClinicalTrials.gov registry record · Phase 3
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 734
- Enrollment target
NCT02006654 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 734 participants.
The verdict
NCT02006654, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 734 participants
- Enrollment target
Study Summary
To establish efficacy of idalopirdine as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).
Interventions
- DRUG Placebo
- DRUG Idalopirdine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 734 participants |
| Start Date | 2014-03 |
| Est. Completion | 2017-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02006654
The ClinicalTrials.gov registry entry for NCT02006654 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 734 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02006654 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02006654 about?
NCT02006654 is a clinical study titled "Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor". To establish efficacy of idalopirdine as adjunctive therapy to acetylcholinesterase inhibitors (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).
What is the current status of trial NCT02006654?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 734 participants. The study started on 2014-03. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02006654?
The interventions under investigation include: Placebo (DRUG), Idalopirdine (DRUG).
Who is sponsoring clinical trial NCT02006654?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.